{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["29(10)"],"submitter":["Westin JR"],"pubmed_abstract":["<h4>Purpose</h4>Older patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) may be considered ineligible for curative-intent therapy including high-dose chemotherapy with autologous stem-cell transplantation (HDT-ASCT). Here, we report outcomes of a preplanned subgroup analysis of patients ≥65 years in ZUMA-7.<h4>Patients and methods</h4>Patients with LBCL refractory to or relapsed ≤12 months after first-line chemoimmunotherapy were randomized 1:1 to axicabtagene ciloleucel [axi-cel; autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy] or standard of care (SOC; 2-3 cycles of chemoimmunotherapy followed by HDT-ASCT). The primary endpoint was event-free survival (EFS). Secondary endpoints included safety and patient-reported outcomes (PROs).<h4>Results</h4>Fift"],"journal":["Clinical cancer research : an official journal of the American Association for Cancer Research"],"pagination":["1894-1905"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10183830"],"repository":["biostudies-literature"],"pubmed_title":["Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma."],"pmcid":["PMC10183830"],"pubmed_authors":["Snider JT","Locke FL","Westin JR","Wulf G","Farooq U","van Meerten T","Shah J","Kersten MJ","Dickinson M","Sureda A","Cheng P","To C","Ulrickson ML","Perales MA","Jacobson CA","Filosto S","Rapoport AP","Leslie L","Oluwole OO","Wannesson L","Pagel JM","Johnston P","Ghobadi A","Elsawy M","Miklos DB","Vardhanabhuti S","Du L"],"additional_accession":[]},"is_claimable":false,"name":"Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma.","description":"<h4>Purpose</h4>Older patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) may be considered ineligible for curative-intent therapy including high-dose chemotherapy with autologous stem-cell transplantation (HDT-ASCT). Here, we report outcomes of a preplanned subgroup analysis of patients ≥65 years in ZUMA-7.<h4>Patients and methods</h4>Patients with LBCL refractory to or relapsed ≤12 months after first-line chemoimmunotherapy were randomized 1:1 to axicabtagene ciloleucel [axi-cel; autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy] or standard of care (SOC; 2-3 cycles of chemoimmunotherapy followed by HDT-ASCT). The primary endpoint was event-free survival (EFS). Secondary endpoints included safety and patient-reported outcomes (PROs).<h4>Results</h4>Fift","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 May","modification":"2025-04-05T10:55:24.059Z","creation":"2025-04-05T10:55:24.059Z"},"accession":"S-EPMC10183830","cross_references":{"pubmed":["36999993"],"doi":["10.1158/1078-0432.CCR-22-3136"]}}